改善病情抗风湿药对类风湿关节炎生育力影响的系统综述
该系统综述检索EMBASE、PubMed和Web of Science Core Collection,评价改善病情抗风湿药(DMARD)是否影响类风湿关节炎(RA)患者的生育力。最终纳入4项仅涉及女性的研究,未报告甲氨蝶呤、培塞利珠单抗、依那西普或柳氮磺吡啶对受孕时间、抗苗勒管激素血清水平或不孕史存在有害影响。作者指出DMARD对生育力可能无有害作用,但男性RA患者证据缺乏,需更多研究。
要点
- 纳入4项仅涉及女性RA患者的研究,未报告DMARD对生育力参数有害。
- 研究涉及甲氨蝶呤、培塞利珠单抗、依那西普和柳氮磺吡啶。
- 男性RA患者DMARD对生育力影响的证据缺乏。
核心结论
- DMARD治疗与一般认知相反,似乎对生育力无有害影响,可能因其带来更好的疾病活动度控制。
- 关于DMARD对女性尤其男性RA患者生育力影响的知识缺口仍存在。
研究设计与样本
- 系统综述,检索EMBASE、PubMed(含MEDLINE)和Web of Science Core Collection,检索日期为2019年10月18日。
- 纳入标准为涉及18岁以上确诊RA并接受DMARD治疗、结局含生育力参数的研究;排除系统综述、meta分析、病例报告、病例系列和动物研究。
- 排除非英语或非荷兰语发表及2004年前发表的研究;质量评价采用CASP系统综述清单。
主要发现
- 去重后识别9030条参考文献,标题/摘要筛选后余82篇,全文筛选后保留4篇,后向滚雪球未发现额外研究。
- 仅能保留涉及女性的研究,这些研究调查了甲氨蝶呤、培塞利珠单抗、依那西普和柳氮磺吡啶对生育力的影响。
- 未报告这些DMARD对受孕时间、抗苗勒管激素血清水平或不孕史存在有害影响。
临床怎么用
- 在RA治疗共同决策中,可参考本综述信息:甲氨蝶呤、培塞利珠单抗、依那西普和柳氮磺吡啶未报告对女性生育力参数有害。
- 对有生育意愿的RA患者,尤其男性,现有证据不足以指导DMARD对生育力影响的咨询。
局限性
- 仅纳入4项研究,且仅涉及女性,男性RA患者证据完全缺乏。
- 排除非英语或非荷兰语发表及2004年前发表的研究,可能遗漏相关证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Drug therapy could alter fertility in patients with rheumatoid arthritis (RA). We aimed to perform a systematic review to evaluate if Disease-modifying antirheumatic drug (DMARD) therapy influences fertility as this is an important point to consider in shared decision making on RA therapy. METHODS: A search was conducted at 18/10/2019 in EMBASE, PubMed (including MEDLINE) and the Web of Science Core Collection. Our inclusion criteria were studies involving women or men diagnosed with RA, older than 18 years and on DMARD therapy, with as outcome a fertility parameter. Systematic reviews, meta-analyses, case reports, case series and animal studies were excluded. Studies not in English or Dutch or published before 2004 were excluded. Quality appraisal was performed by the CASP systematic review checklist. RESULTS: After duplicate removal, 9030 references were identified. After title/abstract screening, 82 articles remained. After full text screening, 4 articles could be retained. No studies were found through backward snowballing. Only studies involving women could be retained. The included studies investigated the effect of methotrexate, certolizumab pegol, etanercept and sulfasalazine on fertility. No detrimental effects of these DMARDs on time-to-pregnancy, anti-Müllerian hormone serum level or presence of a history of infertility, were reported. CONCLUSION: This systematic review underlines the gap in knowledge regarding the effect of DMARDs on fertility in women and especially men with RA. DMARD treatment, contrary to general belief, seemed to have no harmful effect on fertility, possibly because it resulted in better controlled disease activity. More research is needed to improve guidance for patients with RA with a child wish.
引用
- De Cock D, Brants L, Soenen I, et al. A systematic review on the effect of DMARDs on fertility in rheumatoid arthritis. Semin Arthritis Rheum. 2020. PMID: 32896703. doi:10.1016/j.semarthrit.2020.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。